Company intelligence / Profile preview

SulfoSyn

Unclear (possibly UK, based on company type “Limited”—not explicitly confirmed)

Ownership: Private
Development stage: Other

Overview

SulfoSyn has obtained an exclusive global license from Lexaria to apply the DehydraTECH technology to sulforaphane for non-pharmaceutical applications (such as supplements and foods); no clinical or therapeutic studies are reported, as the focus is on consumer wellness rather than drug development

Therapeutic areas: OtherMetabolic Disorders
Modalities: Small moleculeSupplementDietary ingredient
Industry: Food & Nutrition

Partnerships

Lexaria Bioscience (technology licensor, contract manufacturing provider)

Beyond the preview

Go deeper on SulfoSyn.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SulfoSyn.

Explore the full profile